Humanized Target Gene Disease Models

In the realm of biomedical research and the pursuit of innovative clinical treatment strategies, Humanized Genetic Models stand at the forefront, offering a unique window into the intricacies of human biology. By strategically replacing one or more genes with their human counterparts, these models can express complete human proteins or chimeric proteins featuring human-specific structural domains. This revolutionary approach allows researchers to simulate the nuanced processes of human drug action with unprecedented accuracy in the preclinical research environment.

The application of genetically humanized mice spans a wide array of critical areas in biomedical research and clinical development. Notably, these models play a pivotal role in tumor immunotherapy, offering a dynamic platform for assessing CAR-T cell toxicity, testing and validating various immunotherapy approaches, exploring combination immunotherapy strategies, and identifying elusive hematologic disorder targets such as leukemia stem cells and leukemia-initiating cells.

The Cyagen Screening and Evaluation Mouse Model Platform is a trailblazing initiative that provides a diverse range of target gene humanization models to support new drug development, including hF11, B6-hCD47, B6-hPDL1-V, hCTLA4, B6-hIGHG1, and more. To inquire about the development of any genetically humanized mouse model of disease, please contact us – we can create custom genetic humanization models to support your preclinical research and drug discovery.

Below, we present a comprehensive table detailing specific Humanized Target Gene Disease Models offered by the Cyagen Screening and Evaluation Mouse Model Platform. These models, exemplified by strains like B6-hCD47, B6-hPDL1-V, hCTLA4, and more, serve as indispensable tools for researchers navigating the frontier of biomedical innovation. Each product is meticulously designed to contribute to the understanding of diverse diseases, ranging from hematologic disorders to metabolic diseases, and to facilitate the development and validation of novel therapeutic interventions. Click on the corresponding product name to view mouse details and validation data.

Humanized Target Model Categories Product Number Model Name Strain Background Applications
Humanized Immune Checkpoints C001413 B6-hCTLA4 C57BL/6NCya Development and screening of CTLA4-targeted inhibitors/antibody drugs; Evaluation of the efficacy and safety of CTLA4-targeted inhibitors/antibody drugs; Assessment of tumor immunotherapy and research on immune system mechanisms; Research on autoimmune diseases.
C001419 B6-hCD47 C57BL/6JCya Development and screening of CD47-targeted inhibitors/antibody drugs; Evaluation of the efficacy and safety of CD47-targeted inhibitors/antibody drugs; Assessment of tumor immunotherapy and research on tumor immune evasion mechanisms.
C001420 B6-hPDL1-V C57BL/6NCya PDL1 (aka CD274)-targeted drug development, screening, and evaluation of efficacy and safety; Assessment of tumor immunotherapy; Research on the immune system and tumor immune evasion mechanisms.
C001524 hPD-1 C57BL/6JCya Immune checkpoints, tumor research.
Other Humanized Target Models C001272 hF11 C57BL/6NCya Factor XI deficiency, Hemophilia C (Rosenthal syndrome); related to blood clotting disorders
C001400 B6J-hANGPTL3 C57BL/6JCya Research on metabolic diseases such as atherosclerosis and hyperlipidemia; Studies on angiogenesis and endothelial cell adhesion; Development and screening of ANGPTL3-targeted drugs.
C001401 B6-hIGHG1 C57BL/6NCya Research on the mechanisms and pathways of immunoglobulins; Studies on the development and screening of IgG antibody drugs; Research on tumor proliferation, migration, and chemotherapy resistance; Studies on diseases such as chronic lymphocytic leukemia and amyloidosis.
C001421 B6-hGLP-1R C57BL/6NCya Research on the pathogenic mechanisms and drug development screening for obesity and type 2 diabetes; Study of other metabolic diseases such as cardiovascular and myocardial diseases; Research on neuroprotective effects in neurological diseases.
C001492 B6-hALB (HSA) C57BL/6NCya Development and evaluation of ALB-targeted drugs; Design and evaluation of albumin-based drug carriers; Research on ALB-related metabolic diseases.
C001497 B6-hCALCRL C57BL/6JCya Development of migraine treatment drugs, efficacy, and safety evaluation; Research on vascular biology and blood pressure regulation; Study of cell proliferation and apoptosis; Research on tumor growth inhibition and inflammation; Investigation of hematopoietic stem/progenitor cell generation and differentiation.
C001500 B6-hFCGR1 C57BL/6NCya Research on antibody-dependent cell-mediated cytotoxicity (ADCC); Study of immune system phagocytosis and antigen presentation; Assessment of affinity, pharmacology, and efficacy of IgG antibody drugs based on FcγRI receptors.
C001523 B6-hCALCA C57BL/6JCya Migraine drug development, efficacy, and safety evaluation; Vascular biology and blood pressure regulation research; Cell proliferation and apoptosis studies; Tumor growth inhibition and inflammation research; Hematopoietic stem/progenitor cell generation and differentiation research.
C001520 B6-hGDF15 C57BL/6JCya Heart disease, diabetes, anorexia, colorectal cancer, prostate cancer, etc.
C001521 B6-hLPA(CKI) C57BL/6NCya Arteriosclerosis, hyperlipidemia, thrombotic cardiovascular disease.
C001522 B6-hLPA(CKI)/Alb-cre C57BL/6NCya Arteriosclerosis, hyperlipidemia, thrombotic cardiovascular disease.